In particular, we will take into account clinical experience obtained with C5 targeting in different complement‐mediated TMAs to prevent acute mortality from atypical ARDS and/or multiple organ failure in COVID‐19‐affected individuals. The gene discussed is C5; the disease is COVID-19.